Literature DB >> 18469090

Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.

Chen-Lin Hsieh1, Changmeng Cai, Ahmed Giwa, Aaronica Bivins, Shao-Yong Chen, Dina Sabry, Kumara Govardhan, Lirim Shemshedini.   

Abstract

Cellular changes that affect the androgen receptor (AR) can cause prostate cancer to transition from androgen dependent to androgen independent, which is usually lethal. One common change in prostate tumors is overexpression of the AR, which has been shown to lead to androgen-independent growth of prostate cancer cells. This led us to hypothesize that expression of a hyperactive AR would be sufficient for androgen-independent growth of prostate cancer cells. To test this hypothesis, stable lune cancer prostate (LNCaP) cell lines were generated, which express a virion phosphoprotein (VP)16-AR hybrid protein that contains full-length AR fused to the strong viral transcriptional activation domain VP16. This fusion protein elicited as much as a 20-fold stronger transcriptional activity than the natural AR. Stable expression of VP16-AR in LNCaP cells yielded androgen-independent cell proliferation, while under the same growth conditions the parental LNCaP cells exhibited only androgen-dependent growth. These results show that expression of a hyperactive AR is sufficient for androgen-independent growth of prostate cancer cells. To study the molecular basis of this enhanced growth, we measured the expression of soluble guanylyl cyclase-alpha1 (sGCalpha1), a subunit of the sGC, an androgen-regulated gene that has been shown to be involved in prostate cancer cell growth. Interestingly, the expression of sGCalpha1 is androgen independent in VP16-AR-expressing cells, in contrast to its androgen-induced expression in control LNCaP cells. RNA(I)-dependent inhibition of sGCalpha1 expression resulted in significantly reduced proliferation of VP16-AR cells, implicating an important role for sGCalpha1 in the androgen-independent growth of these cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469090     DOI: 10.1677/JME-07-0158

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  2 in total

1.  The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.

Authors:  L Wang; G Song; X Chang; W Tan; J Pan; X Zhu; Z Liu; M Qi; J Yu; B Han
Journal:  Oncogene       Date:  2014-12-15       Impact factor: 9.867

2.  Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1.

Authors:  Yiming Zhang; Binshen Chen; Naijin Xu; Peng Xu; Wenfeng Lin; Chunxiao Liu; Peng Huang
Journal:  Int J Nanomedicine       Date:  2021-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.